Expression of Optic Atrophy Type 1 (OPA1) Protein in Lung Adenocarcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01249053

Enrollment

100

Registered

2010-11-29

Start date

2010-08-31

Completion date

Unknown

Last updated

2010-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Adenocarcinoma

Keywords

OPA1, lung adenocarcinomas, Prognosis, Expression of optic atrophy type 1 (OPA1) protein in lung adenocarcinoma

Brief summary

Optic atrophy type 1(OPA1) is a nuclear dynamin-related GTPase, targeted to the inner mitochondrial membrane, which plays a role in mitochondrial fusion. Mitochondria fusion is associated with process of apoptosis. . OPA1 plays an important role in the mitochondrial bioenergetics and mitochondrial networks. The changes in mitochondrial shape and mitochondrial bioenergetics may be cause of the disease. In this study, we investigate the expression of OPA1 in lung adenocarcinoma (LADC) cells and tissue.

Interventions

None listed

Study design

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

25 Years to 85 Years

Healthy volunteers

Inclusion criteria

* We will collect paraffin blocked resected lung tissue samples from stage I\ IIIa non-small cell lung cancer patients (age, 40\ 80 years old) who received lobectomy of the affected lung.

Exclusion criteria

* History of uremia, other malignant disease, and liver cirrhosis * History of pneumonia and pulmonary tuberculosis * History of long period of medications.

Countries

Taiwan

Outcome results